RxDoctor Payments Data

Matthew Ricks, DO

Surgery · Saint Louis, MONPI 1902055296

Payments from drug & device makers

$485in general payments, 2019–2025

Across 19 payments — averaging $25.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$104
  • Endo Pharmaceuticals Inc.$96
  • Covidien LP$85
  • Novo Nordisk$62
  • Lilly USA, LLC$61
  • Takeda Pharmaceuticals U.S.A., Inc.$20
  • plus $57 from 4 others

What the payments were for

  • Food & beverage$485100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$485 in reported general payments places this provider in the 30th percentile of 612 surgery providers in Missouri.

See all surgery providers in Missouri

Medicare billing

Part B allowed, 2024
$59,790
Medicare patients
120
Services billed
267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide22$11,960
MotegrityPrucalopride Succinate12$7,475
Sucralfate83$2,270
Dexlansoprazole DrDexlansoprazole14$2,243
Cholestyramine LightCholestyramine14$1,621
Colestipol Hcl32$1,459
CholestyramineCholestyramine (With Sugar)13$1,382
Pantoprazole Sodium239$1,316
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen88$546
Ondansetron OdtOndansetron34$375
Famotidine22$284
Metoclopramide Hcl38$270
Gabapentin18$130
Methylprednisolone12$76
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$20$7,47512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 612 surgery providers in Missouri.

Other surgery in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →